Medulloblastoma and central nervous system germ cell tumors in adults: is pediatric experience applicable?

Maurizio Mascarin, Elisa Coassin, Enrico Franceschi, Lorenza Gandola, Giorgio Carrabba, Alba A. Brandes, Maura Massimino

Research output: Contribution to journalReview article

Abstract

Medulloblastoma and central nervous system (CNS) germ cell tumors are very rare in adults, while they account for 25% and 5% of brain tumors in children, respectively (Pastore et al. Eur J Cancer 42:2064–208, 2006). Pediatric experiences, mostly from randomized and controlled clinical trials, have led to different tailored treatments, based on various risk factors, including histology, and extent of disease. For medulloblastoma, biological features have recently emerged that enable therapies to be scaled down in some cases, or pursued more aggressively in the event of chromosomal and/or genetic alterations (Massimino et al. Crit Rev Oncol Hematol 105:35–51, 2016). Such refinements are still impossible for adult patients due to the lack of similar clinical trials that might provide the same or a different understanding regarding patients’ prognosis, long-term survival, quality of life, and acute and late toxicities. This review aims to contribute to the debate on the treatment of adults with these two diseases and promote the creation of broad-based, national and international trials to advance our knowledge in this area and to share the skills between pediatric and adult oncologists as adolescent and young adults (AYA) brain tumor national boards are currently requiring.

Original languageEnglish
Pages (from-to)2279-2287
JournalChild's Nervous System
Volume35
Issue number12
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Nervous System Neoplasms
Medulloblastoma
Germ Cell and Embryonal Neoplasms
Central Nervous System
Pediatrics
Brain Neoplasms
Young Adult
Histology
Therapeutics
Randomized Controlled Trials
Quality of Life
Clinical Trials
Survival
Neoplasms

Keywords

  • Adults
  • Childhood cancers
  • CNS germ cell tumors
  • Medulloblastoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Clinical Neurology

Cite this

Medulloblastoma and central nervous system germ cell tumors in adults : is pediatric experience applicable? / Mascarin, Maurizio; Coassin, Elisa; Franceschi, Enrico; Gandola, Lorenza; Carrabba, Giorgio; Brandes, Alba A.; Massimino, Maura.

In: Child's Nervous System, Vol. 35, No. 12, 01.01.2019, p. 2279-2287.

Research output: Contribution to journalReview article

@article{9ceac762d1de4abd8383889378fda17c,
title = "Medulloblastoma and central nervous system germ cell tumors in adults: is pediatric experience applicable?",
abstract = "Medulloblastoma and central nervous system (CNS) germ cell tumors are very rare in adults, while they account for 25{\%} and 5{\%} of brain tumors in children, respectively (Pastore et al. Eur J Cancer 42:2064–208, 2006). Pediatric experiences, mostly from randomized and controlled clinical trials, have led to different tailored treatments, based on various risk factors, including histology, and extent of disease. For medulloblastoma, biological features have recently emerged that enable therapies to be scaled down in some cases, or pursued more aggressively in the event of chromosomal and/or genetic alterations (Massimino et al. Crit Rev Oncol Hematol 105:35–51, 2016). Such refinements are still impossible for adult patients due to the lack of similar clinical trials that might provide the same or a different understanding regarding patients’ prognosis, long-term survival, quality of life, and acute and late toxicities. This review aims to contribute to the debate on the treatment of adults with these two diseases and promote the creation of broad-based, national and international trials to advance our knowledge in this area and to share the skills between pediatric and adult oncologists as adolescent and young adults (AYA) brain tumor national boards are currently requiring.",
keywords = "Adults, Childhood cancers, CNS germ cell tumors, Medulloblastoma",
author = "Maurizio Mascarin and Elisa Coassin and Enrico Franceschi and Lorenza Gandola and Giorgio Carrabba and Brandes, {Alba A.} and Maura Massimino",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s00381-019-04340-8",
language = "English",
volume = "35",
pages = "2279--2287",
journal = "Child's Nervous System",
issn = "0256-7040",
publisher = "Springer Verlag",
number = "12",

}

TY - JOUR

T1 - Medulloblastoma and central nervous system germ cell tumors in adults

T2 - is pediatric experience applicable?

AU - Mascarin, Maurizio

AU - Coassin, Elisa

AU - Franceschi, Enrico

AU - Gandola, Lorenza

AU - Carrabba, Giorgio

AU - Brandes, Alba A.

AU - Massimino, Maura

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Medulloblastoma and central nervous system (CNS) germ cell tumors are very rare in adults, while they account for 25% and 5% of brain tumors in children, respectively (Pastore et al. Eur J Cancer 42:2064–208, 2006). Pediatric experiences, mostly from randomized and controlled clinical trials, have led to different tailored treatments, based on various risk factors, including histology, and extent of disease. For medulloblastoma, biological features have recently emerged that enable therapies to be scaled down in some cases, or pursued more aggressively in the event of chromosomal and/or genetic alterations (Massimino et al. Crit Rev Oncol Hematol 105:35–51, 2016). Such refinements are still impossible for adult patients due to the lack of similar clinical trials that might provide the same or a different understanding regarding patients’ prognosis, long-term survival, quality of life, and acute and late toxicities. This review aims to contribute to the debate on the treatment of adults with these two diseases and promote the creation of broad-based, national and international trials to advance our knowledge in this area and to share the skills between pediatric and adult oncologists as adolescent and young adults (AYA) brain tumor national boards are currently requiring.

AB - Medulloblastoma and central nervous system (CNS) germ cell tumors are very rare in adults, while they account for 25% and 5% of brain tumors in children, respectively (Pastore et al. Eur J Cancer 42:2064–208, 2006). Pediatric experiences, mostly from randomized and controlled clinical trials, have led to different tailored treatments, based on various risk factors, including histology, and extent of disease. For medulloblastoma, biological features have recently emerged that enable therapies to be scaled down in some cases, or pursued more aggressively in the event of chromosomal and/or genetic alterations (Massimino et al. Crit Rev Oncol Hematol 105:35–51, 2016). Such refinements are still impossible for adult patients due to the lack of similar clinical trials that might provide the same or a different understanding regarding patients’ prognosis, long-term survival, quality of life, and acute and late toxicities. This review aims to contribute to the debate on the treatment of adults with these two diseases and promote the creation of broad-based, national and international trials to advance our knowledge in this area and to share the skills between pediatric and adult oncologists as adolescent and young adults (AYA) brain tumor national boards are currently requiring.

KW - Adults

KW - Childhood cancers

KW - CNS germ cell tumors

KW - Medulloblastoma

UR - http://www.scopus.com/inward/record.url?scp=85071028949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071028949&partnerID=8YFLogxK

U2 - 10.1007/s00381-019-04340-8

DO - 10.1007/s00381-019-04340-8

M3 - Review article

AN - SCOPUS:85071028949

VL - 35

SP - 2279

EP - 2287

JO - Child's Nervous System

JF - Child's Nervous System

SN - 0256-7040

IS - 12

ER -